Effects of GST variants on the risk odds of hematological malignancy: A meta-analysis.

gene polymorphisms glutathione S-transferases (GST) hematological malignancy meta-analysis

Journal

Journal of cellular biochemistry
ISSN: 1097-4644
Titre abrégé: J Cell Biochem
Pays: United States
ID NLM: 8205768

Informations de publication

Date de publication:
May 2019
Historique:
received: 17 10 2018
accepted: 05 11 2018
pubmed: 12 12 2018
medline: 12 12 2018
entrez: 12 12 2018
Statut: ppublish

Résumé

Whether glutathione S-transferases (GST) polymorphisms influence the risk odds of hematological malignancy remains controversial. Therefore, we performed this meta-analysis to better analyze correlations between GST polymorphisms and hematological malignancy. Literature retrieve was conducted in PubMed, MEDLINE, and Embase. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated. Sixty-two studies were enrolled for analyses. Significant associations with hematological malignancy were observed for GSTM1 (P < 0.0001, OR = 1.25, 95% CI, 1.14-1.38), GSTP1 (P = 0.002, OR = 1.20, 95% CI, 1.07-1.34), and GSTT1 (P < 0.0001, OR = 1.57, 95% CI, 1.39-1.76) polymorphisms in overall analyses. Further subgroup analyses by ethnicity revealed that GSTM1 and GSTT1 polymorphisms were both significantly correlated with hematological malignancy in Caucasians, East Asians, and West Asians, whereas GSTP1 polymorphism was only significantly correlated with hematological malignancy in Caucasians and West Asians. When we stratified data according to type of disease, positive results were found for all investigated polymorphisms in patients with certain types of acute leukemia. Moreover, GSTP1 polymorphism was also found to be significantly associated with chronic leukemia and lymphoma. Our findings indicated that GSTM1, GSTT1, and GSTP1 polymorphisms may serve as potential genetic biomarkers of hematological malignancy in certain ethnicities.

Sections du résumé

BACKGROUND BACKGROUND
Whether glutathione S-transferases (GST) polymorphisms influence the risk odds of hematological malignancy remains controversial. Therefore, we performed this meta-analysis to better analyze correlations between GST polymorphisms and hematological malignancy.
METHODS METHODS
Literature retrieve was conducted in PubMed, MEDLINE, and Embase. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated.
RESULTS RESULTS
Sixty-two studies were enrolled for analyses. Significant associations with hematological malignancy were observed for GSTM1 (P < 0.0001, OR = 1.25, 95% CI, 1.14-1.38), GSTP1 (P = 0.002, OR = 1.20, 95% CI, 1.07-1.34), and GSTT1 (P < 0.0001, OR = 1.57, 95% CI, 1.39-1.76) polymorphisms in overall analyses. Further subgroup analyses by ethnicity revealed that GSTM1 and GSTT1 polymorphisms were both significantly correlated with hematological malignancy in Caucasians, East Asians, and West Asians, whereas GSTP1 polymorphism was only significantly correlated with hematological malignancy in Caucasians and West Asians. When we stratified data according to type of disease, positive results were found for all investigated polymorphisms in patients with certain types of acute leukemia. Moreover, GSTP1 polymorphism was also found to be significantly associated with chronic leukemia and lymphoma.
CONCLUSIONS CONCLUSIONS
Our findings indicated that GSTM1, GSTT1, and GSTP1 polymorphisms may serve as potential genetic biomarkers of hematological malignancy in certain ethnicities.

Identifiants

pubmed: 30537151
doi: 10.1002/jcb.28145
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

8570-8580

Informations de copyright

© 2018 Wiley Periodicals, Inc.

Auteurs

Minjie Li (M)

Department of Medical Oncology, Linyi Cancer Hospital, Linyi, Shandong, China.

Meifang Zheng (M)

Department of Medical Oncology, Linyi Cancer Hospital, Linyi, Shandong, China.

Hongyun Chen (H)

Department of Medical Oncology, Linyi Cancer Hospital, Linyi, Shandong, China.

Haiqing Yu (H)

Department of Medical Oncology, Linyi Cancer Hospital, Linyi, Shandong, China.

Classifications MeSH